![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Press Releases
NovaBay Pharmaceuticals Reports Activity of Aganocide NVC-422 Against Deadly Superbug
NovaBay Pharmaceuticals, a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, announces that in tests conducted...
Press Releases
Lundbeck phase III studies confirm nalmefene as efficacious and safe in helping individuals to reduce their alcohol consumption
H. Lundbeck A/S (Lundbeck) announced the completion of two out of three pivotal studies in the phase III clinical programme for nalmefene in alcohol...
Press Releases
Personalised Medicine and Diagnostics Europe 2011
Innovate in an era of cost-effectiveness: Realise the value of personalised medicine Discover how to strengthen your drug pipeline with companion diagnostics How...
Press Releases
King Pharmaceuticals and Pain Therapeutics Announce Resubmission of New Drug Application for REMOXY
King Pharmaceuticals, Inc. and Pain Therapeutics, Inc. announced that King has resubmitted a New Drug Application (NDA) for REMOXY (oxycodone) to the U.S. Food...
Press Releases
Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery
Sanofi-aventis and Ascendis Pharma (Ascendis) announced a global licensing and patent transfer agreement on Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, which allows...
Press Releases
Bristol-Myers Squibb Company and Pfizer Inc.announced that the ADVANCE-3 study results
Bristol-Myers Squibb Company and Pfizer Inc.announced that the ADVANCE-3 study results, published in The New England Journal of Medicine, showed apixaban was statistically superior...
Press Releases
Novartis drug Tasigna approved in Japan for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
Novartis has received approval from Japan's Ministry of Health, Labour and Welfare to offer Tasigna® (nilotinib) as a treatment for adult patients with newly...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read